Entropy NeurodynamicsTYPTF Cash Ratio is 5.70 as of Dec. 2025, which is 19% above its 10-year median of 4.77. The stock has 5 warning signs investors should review. Among 1,386 Biotechnology companies, Entropy Neurodynamics ranks better than 66.59% on this metric.
Entropy Neurodynamics has a Cash Ratio of 5.70. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Entropy Neurodynamics's Cash Ratio or its related term are showing as below:
TYPTF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.85 Med: 4.77 Max: 94.97
Current: 5.7
During the past 7 years, Entropy Neurodynamics's highest Cash Ratio was 94.97. The lowest was 0.85. And the median was 4.77.
TYPTF's Cash Ratio is ranked better than 66.59% of 1386
companies
in the Biotechnology industry
Industry Median: 2.94
vs TYPTF: 5.70
Entropy Neurodynamics (OTCPK:TYPTF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entropy Neurodynamics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics (TYPTF) has a Cash Ratio of 5.70 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Entropy Neurodynamics and its competitors. This is 19% above median its historical median of 4.77. Over the past decade, Entropy Neurodynamics' Cash Ratio has ranged from 0.85 to 94.97. According to the industry distribution chart, Entropy Neurodynamics ranks #463 out of 1386 companies in the Biotechnology industry, placing it in the top 33.4%.
Is Entropy Neurodynamics' Cash Ratio too high?
Entropy Neurodynamics' current Cash Ratio of 5.70 is 19% above median its 10-year median of 4.77. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 94.97. The Biotechnology industry median Cash Ratio is 2.94. Entropy Neurodynamics' value of 5.70 is 93.9% above this industry median. Based on the distribution chart, Entropy Neurodynamics ranks #463 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entropy Neurodynamics' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #463 out of 1386 companies for Cash Ratio. This puts Entropy Neurodynamics in the upper half of its industry. The industry median Cash Ratio is 2.94. Entropy Neurodynamics' value of 5.70 is 93.9% above this benchmark. Historically, Entropy Neurodynamics' own Cash Ratio has ranged from 0.85 to 94.97 over the past decade. While the company's 10-year median is 4.77 vs. the industry median of 2.94, Entropy Neurodynamics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entropy Neurodynamics's current Cash Ratio of 5.70 is 93.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Entropy Neurodynamics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current Cash Ratio is 5.70, which is 19% above median its own 10-year median of 4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Cash Ratio is 5.70, which is 19% above median its 10-year median of 4.77 and 93.9% above the Biotechnology industry median of 2.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Cash Ratio is 5.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 